Effectiveness of Hypertension Management Strategies in SPRINT-Eligible US Adults: A Simulation Study

Despite reducing cardiovascular disease (CVD) events and death in SPRINT (Systolic Blood Pressure Intervention Trial), intensive systolic blood pressure goals have not been adopted in the United States. This study aimed to simulate the potential long-term impact of 4 hypertension management strategi...

Full description

Saved in:
Bibliographic Details
Published inJournal of the American Heart Association Vol. 13; no. 2; p. e032370
Main Authors Zhang, Fengdi, Bryant, Kelsey B, Moran, Andrew E, Zhang, Yiyi, Cohen, Jordana B, Bress, Adam P, Sheppard, James P, King, Jordan B, Derington, Catherine G, Weintraub, William S, Kronish, Ian M, Shea, Steven, Bellows, Brandon K
Format Journal Article
LanguageEnglish
Published England John Wiley and Sons Inc 16.01.2024
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Despite reducing cardiovascular disease (CVD) events and death in SPRINT (Systolic Blood Pressure Intervention Trial), intensive systolic blood pressure goals have not been adopted in the United States. This study aimed to simulate the potential long-term impact of 4 hypertension management strategies in SPRINT-eligible US adults. The validated Blood Pressure Control-Cardiovascular Disease Policy Model, a discrete event simulation of hypertension care processes (ie, visit frequency, blood pressure [BP] measurement accuracy, medication intensification, and medication adherence) and CVD outcomes, was populated with 25 000 SPRINT-eligible US adults. Four hypertension management strategies were simulated: (1) usual care targeting BP <140/90 mm Hg (Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure usual care), (2) intensive care per the SPRINT protocol targeting BP <120/90 mm Hg (SPRINT intensive), (3) usual care targeting guideline-recommended BP <130/80 mm Hg (American College of Cardiology/American Heart Association usual care), and (4) team-based care added to usual care and targeting BP <130/80 mm Hg. Relative to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure usual care, among the 18.1 million SPRINT-eligible US adults, an estimated 138 100 total CVD events could be prevented per year with SPRINT intensive, 33 900 with American College of Cardiology/American Heart Association usual care, and 89 100 with team-based care. Compared with the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure usual care, SPRINT intensive care was projected to increase treatment-related serious adverse events by 77 600 per year, American College of Cardiology/American Heart Association usual care by 33 300, and team-based care by 27 200. As BP control has declined in recent years, health systems must prioritize hypertension management and invest in effective strategies. Adding team-based care to usual care may be a pragmatic way to manage risk in this high-CVD-risk population.
AbstractList BACKGROUNDDespite reducing cardiovascular disease (CVD) events and death in SPRINT (Systolic Blood Pressure Intervention Trial), intensive systolic blood pressure goals have not been adopted in the United States. This study aimed to simulate the potential long-term impact of 4 hypertension management strategies in SPRINT-eligible US adults.METHODS AND RESULTSThe validated Blood Pressure Control-Cardiovascular Disease Policy Model, a discrete event simulation of hypertension care processes (ie, visit frequency, blood pressure [BP] measurement accuracy, medication intensification, and medication adherence) and CVD outcomes, was populated with 25 000 SPRINT-eligible US adults. Four hypertension management strategies were simulated: (1) usual care targeting BP <140/90 mm Hg (Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure usual care), (2) intensive care per the SPRINT protocol targeting BP <120/90 mm Hg (SPRINT intensive), (3) usual care targeting guideline-recommended BP <130/80 mm Hg (American College of Cardiology/American Heart Association usual care), and (4) team-based care added to usual care and targeting BP <130/80 mm Hg. Relative to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure usual care, among the 18.1 million SPRINT-eligible US adults, an estimated 138 100 total CVD events could be prevented per year with SPRINT intensive, 33 900 with American College of Cardiology/American Heart Association usual care, and 89 100 with team-based care. Compared with the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure usual care, SPRINT intensive care was projected to increase treatment-related serious adverse events by 77 600 per year, American College of Cardiology/American Heart Association usual care by 33 300, and team-based care by 27 200.CONCLUSIONSAs BP control has declined in recent years, health systems must prioritize hypertension management and invest in effective strategies. Adding team-based care to usual care may be a pragmatic way to manage risk in this high-CVD-risk population.
Despite reducing cardiovascular disease (CVD) events and death in SPRINT (Systolic Blood Pressure Intervention Trial), intensive systolic blood pressure goals have not been adopted in the United States. This study aimed to simulate the potential long-term impact of 4 hypertension management strategies in SPRINT-eligible US adults. The validated Blood Pressure Control-Cardiovascular Disease Policy Model, a discrete event simulation of hypertension care processes (ie, visit frequency, blood pressure [BP] measurement accuracy, medication intensification, and medication adherence) and CVD outcomes, was populated with 25 000 SPRINT-eligible US adults. Four hypertension management strategies were simulated: (1) usual care targeting BP <140/90 mm Hg (Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure usual care), (2) intensive care per the SPRINT protocol targeting BP <120/90 mm Hg (SPRINT intensive), (3) usual care targeting guideline-recommended BP <130/80 mm Hg (American College of Cardiology/American Heart Association usual care), and (4) team-based care added to usual care and targeting BP <130/80 mm Hg. Relative to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure usual care, among the 18.1 million SPRINT-eligible US adults, an estimated 138 100 total CVD events could be prevented per year with SPRINT intensive, 33 900 with American College of Cardiology/American Heart Association usual care, and 89 100 with team-based care. Compared with the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure usual care, SPRINT intensive care was projected to increase treatment-related serious adverse events by 77 600 per year, American College of Cardiology/American Heart Association usual care by 33 300, and team-based care by 27 200. As BP control has declined in recent years, health systems must prioritize hypertension management and invest in effective strategies. Adding team-based care to usual care may be a pragmatic way to manage risk in this high-CVD-risk population.
Background Despite reducing cardiovascular disease (CVD) events and death in SPRINT (Systolic Blood Pressure Intervention Trial), intensive systolic blood pressure goals have not been adopted in the United States. This study aimed to simulate the potential long‐term impact of 4 hypertension management strategies in SPRINT‐eligible US adults. Methods and Results The validated Blood Pressure Control–Cardiovascular Disease Policy Model, a discrete event simulation of hypertension care processes (ie, visit frequency, blood pressure [BP] measurement accuracy, medication intensification, and medication adherence) and CVD outcomes, was populated with 25 000 SPRINT‐eligible US adults. Four hypertension management strategies were simulated: (1) usual care targeting BP <140/90 mm Hg (Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure usual care), (2) intensive care per the SPRINT protocol targeting BP <120/90 mm Hg (SPRINT intensive), (3) usual care targeting guideline‐recommended BP <130/80 mm Hg (American College of Cardiology/American Heart Association usual care), and (4) team‐based care added to usual care and targeting BP <130/80 mm Hg. Relative to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure usual care, among the 18.1 million SPRINT‐eligible US adults, an estimated 138 100 total CVD events could be prevented per year with SPRINT intensive, 33 900 with American College of Cardiology/American Heart Association usual care, and 89 100 with team‐based care. Compared with the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure usual care, SPRINT intensive care was projected to increase treatment‐related serious adverse events by 77 600 per year, American College of Cardiology/American Heart Association usual care by 33 300, and team‐based care by 27 200. Conclusions As BP control has declined in recent years, health systems must prioritize hypertension management and invest in effective strategies. Adding team‐based care to usual care may be a pragmatic way to manage risk in this high‐CVD‐risk population.
Author Kronish, Ian M
Bryant, Kelsey B
Weintraub, William S
Bress, Adam P
Cohen, Jordana B
Derington, Catherine G
Zhang, Yiyi
King, Jordan B
Zhang, Fengdi
Shea, Steven
Sheppard, James P
Moran, Andrew E
Bellows, Brandon K
AuthorAffiliation 7 Department of Medicine Georgetown University Washington DC USA
2 Department of Medicine Mount Sinai New York NY USA
4 Intermountain Healthcare Department of Population Health Sciences University of Utah Salt Lake City UT USA
6 Institute for Health Research Kaiser Permanente Colorado Aurora CO USA
3 Department of Medicine and Department of Biostatistics, Epidemiology, and Informatics University of Pennsylvania Philadelphia PA USA
5 Nuffield Department of Primary Care Health Sciences University of Oxford UK
1 Department of Medicine Columbia University New York NY USA
8 MedStar Health Research Institute Washington DC USA
AuthorAffiliation_xml – name: 5 Nuffield Department of Primary Care Health Sciences University of Oxford UK
– name: 6 Institute for Health Research Kaiser Permanente Colorado Aurora CO USA
– name: 3 Department of Medicine and Department of Biostatistics, Epidemiology, and Informatics University of Pennsylvania Philadelphia PA USA
– name: 1 Department of Medicine Columbia University New York NY USA
– name: 4 Intermountain Healthcare Department of Population Health Sciences University of Utah Salt Lake City UT USA
– name: 2 Department of Medicine Mount Sinai New York NY USA
– name: 8 MedStar Health Research Institute Washington DC USA
– name: 7 Department of Medicine Georgetown University Washington DC USA
Author_xml – sequence: 1
  givenname: Fengdi
  orcidid: 0009-0002-2380-0708
  surname: Zhang
  fullname: Zhang, Fengdi
  organization: Department of Medicine Columbia University New York NY USA
– sequence: 2
  givenname: Kelsey B
  orcidid: 0000-0001-7180-8064
  surname: Bryant
  fullname: Bryant, Kelsey B
  organization: Department of Medicine Mount Sinai New York NY USA
– sequence: 3
  givenname: Andrew E
  orcidid: 0000-0003-3554-0085
  surname: Moran
  fullname: Moran, Andrew E
  organization: Department of Medicine Columbia University New York NY USA
– sequence: 4
  givenname: Yiyi
  orcidid: 0000-0002-8663-5001
  surname: Zhang
  fullname: Zhang, Yiyi
  organization: Department of Medicine Columbia University New York NY USA
– sequence: 5
  givenname: Jordana B
  orcidid: 0000-0003-4649-079X
  surname: Cohen
  fullname: Cohen, Jordana B
  organization: Department of Medicine and Department of Biostatistics, Epidemiology, and Informatics University of Pennsylvania Philadelphia PA USA
– sequence: 6
  givenname: Adam P
  orcidid: 0000-0002-2259-5039
  surname: Bress
  fullname: Bress, Adam P
  organization: Intermountain Healthcare Department of Population Health Sciences University of Utah Salt Lake City UT USA
– sequence: 7
  givenname: James P
  orcidid: 0000-0002-4461-8756
  surname: Sheppard
  fullname: Sheppard, James P
  organization: Nuffield Department of Primary Care Health Sciences University of Oxford UK
– sequence: 8
  givenname: Jordan B
  orcidid: 0000-0002-6783-7951
  surname: King
  fullname: King, Jordan B
  organization: Institute for Health Research Kaiser Permanente Colorado Aurora CO USA
– sequence: 9
  givenname: Catherine G
  orcidid: 0000-0001-7382-4607
  surname: Derington
  fullname: Derington, Catherine G
  organization: Intermountain Healthcare Department of Population Health Sciences University of Utah Salt Lake City UT USA
– sequence: 10
  givenname: William S
  orcidid: 0000-0002-5384-5571
  surname: Weintraub
  fullname: Weintraub, William S
  organization: MedStar Health Research Institute Washington DC USA
– sequence: 11
  givenname: Ian M
  orcidid: 0000-0003-0945-2380
  surname: Kronish
  fullname: Kronish, Ian M
  organization: Department of Medicine Columbia University New York NY USA
– sequence: 12
  givenname: Steven
  orcidid: 0000-0002-7382-0603
  surname: Shea
  fullname: Shea, Steven
  organization: Department of Medicine Columbia University New York NY USA
– sequence: 13
  givenname: Brandon K
  orcidid: 0000-0003-1395-6047
  surname: Bellows
  fullname: Bellows, Brandon K
  organization: Department of Medicine Columbia University New York NY USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38214272$$D View this record in MEDLINE/PubMed
BookMark eNpVkUtP3DAQgKOKqlDKubcqx16y-BXH7qWK0La7FX2ogbPlOOPUKI_FdpD23_S38MtIuhSBL7Zmxt-M5nubHA3jAEnyHqMVxhyffys35QoTukKU0AK9Sk4IYkUmpUBHz97HyVkIN2g-nBQ0l2-SYyoIZqQgJwmsrQUT3R0MEEI62nSz34GPMAQ3Dul3PegWehhiWkWvI7QOQuqGtPr1e_vjKlt3rnV1B-l1lZbN1MXwKS3v_1aunzodF0IVp2b_LnltdRfg7PE-Ta6_rK8uNtnlz6_bi_IyM4yjmEmKQRomiCWkkJbmhnJmG1xYblhNhNTCCoNqgW1dMF0DxzXWAmouWcGIoKfJ9sBtRn2jdt712u_VqJ36Fxh9q7SPznSgCs45MwLlDaeMWDpD541xBrUEmXMysz4fWLup7qEx8w687l5AX2YG90e1453CSBIu0EL4-Ejw4-0EIareBQNdpwcYp6CIxHleYMyWwc8PpcaPIXiwT30wUotstchWs2x1kD3_-PB8vKf6_2rpA8xLpqw
CitedBy_id crossref_primary_10_1152_ajpheart_00052_2024
Cites_doi 10.1161/01.CIR.0000017861.00991.2F
10.1161/CIRCULATIONAHA.113.004046
10.1016/j.amjcard.2010.09.026
10.1016/j.jacc.2019.03.529
10.1093/aje/kwy139
10.1016/S0140-6736(15)00805-3
10.1161/CIRCHEARTFAILURE.115.002460
10.1161/CIRCOUTCOMES.118.005624
10.1001/jamacardio.2019.6192
10.1001/jama.2016.7050
10.1093/ije/dyy264
10.1016/S0149-2918(01)80109-0
10.1161/CIRCULATIONAHA.116.025322
10.1001/jamacardio.2021.3508
10.3310/hta7310
10.1161/JAHA.120.016174
10.1161/CIR.0000000000000758
10.1016/S0140-6736(15)01225-8
10.7326/M17-1805
10.1177/0272989X06290495
10.1001/jamainternmed.2020.0051
10.1001/jama.289.19.2560
10.1136/bmj.39553.670231.25
10.1093/ajh/hpad047
10.1161/HYPERTENSIONAHA.109.148791
10.1161/HYPERTENSIONAHA.122.20292
10.1016/j.amepre.2014.03.004
10.1161/CIRCULATIONAHA.120.051683
10.3399/BJGP.2022.0389
10.1001/jamanetworkopen.2021.43001
10.1016/S0140-6736(12)61689-4
10.1093/ajh/hpy053
10.1136/bmj.326.7404.1427
10.1161/CIRCULATIONAHA.113.007787
10.1371/journal.pmed.1004223
10.1056/NEJMsa1616035
10.1016/j.cardfail.2019.07.134
10.1161/01.CIR.0000109691.16944.DA
10.1111/jgs.16749
10.1161/JAHA.120.020361
10.1056/NEJMoa1717250
10.1161/CIRCULATIONAHA.113.004042
10.1161/CIRCULATIONAHA.118.038165
10.1038/s41371-023-00811-3
10.1161/HYP.0000000000000065
10.1016/j.jchf.2016.02.007
10.1161/JAHA.120.019707
10.1001/jamacardio.2016.3517
10.1016/j.jacc.2021.02.058
10.1056/NEJMoa1511939
ContentType Journal Article
Copyright 2024 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
Copyright_xml – notice: 2024 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.1161/JAHA.123.032370
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Management Strategies in SPRINT‐Eligible US Adults
EISSN 2047-9980
EndPage e032370
ExternalDocumentID oai_doaj_org_article_76664c805d6342f3b8120464eb9e9562
10_1161_JAHA_123_032370
38214272
Genre Journal Article
GeographicLocations United States
GeographicLocations_xml – name: United States
GrantInformation_xml – fundername: NHLBI NIH HHS
  grantid: K01 HL140170
– fundername: NHLBI NIH HHS
  grantid: R01 HL157439
– fundername: NHLBI NIH HHS
  grantid: R01 HL152699
– fundername: NIA NIH HHS
  grantid: K24 AG080168
– fundername: NHLBI NIH HHS
  grantid: R01 HL130500
– fundername: NIA NIH HHS
  grantid: R01 AG065805
– fundername: NHLBI NIH HHS
  grantid: R01 HL158790
– fundername: Royal Society via a Sir Henry Dale Fellowship
  grantid: 211182/Z/18/Z
GroupedDBID 0R~
1OC
24P
53G
5VS
8-1
AAZKR
ACGFO
ACXQS
ADBBV
ADKYN
ADZMN
AEGXH
AENEX
AIAGR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AVUZU
BAWUL
BCNDV
CGR
CUY
CVF
DIK
EBS
ECM
EIF
EMOBN
GODZA
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
NPM
OK1
RAH
RHF
RNS
RPM
WIN
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c460t-931e9c482f2279f35c364fd17f6c4b289a8f8c0b81fb74abe61b1a8eb69474283
IEDL.DBID RPM
ISSN 2047-9980
IngestDate Tue Oct 22 15:14:57 EDT 2024
Tue Sep 17 21:29:10 EDT 2024
Thu Oct 24 20:33:08 EDT 2024
Fri Dec 06 02:10:21 EST 2024
Sat Nov 02 12:27:26 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords blood pressure
hypertension
cardiovascular diseases
Language English
License This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c460t-931e9c482f2279f35c364fd17f6c4b289a8f8c0b81fb74abe61b1a8eb69474283
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This manuscript was sent to Tazeen H. Jafar, MD MPH, Associate Editor, for review by expert referees, editorial decision, and final disposition.
For Sources of Funding and Disclosures, see page 9.
Supplemental Material is available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.123.032370
ORCID 0009-0002-2380-0708
0000-0001-7180-8064
0000-0001-7382-4607
0000-0003-3554-0085
0000-0002-4461-8756
0000-0002-6783-7951
0000-0003-0945-2380
0000-0003-4649-079X
0000-0002-5384-5571
0000-0002-2259-5039
0000-0002-8663-5001
0000-0002-7382-0603
0000-0003-1395-6047
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10926802/
PMID 38214272
PQID 2915571148
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_76664c805d6342f3b8120464eb9e9562
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10926802
proquest_miscellaneous_2915571148
crossref_primary_10_1161_JAHA_123_032370
pubmed_primary_38214272
PublicationCentury 2000
PublicationDate 2024-01-16
PublicationDateYYYYMMDD 2024-01-16
PublicationDate_xml – month: 01
  year: 2024
  text: 2024-01-16
  day: 16
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Hoboken
PublicationTitle Journal of the American Heart Association
PublicationTitleAlternate J Am Heart Assoc
PublicationYear 2024
Publisher John Wiley and Sons Inc
Wiley
Publisher_xml – name: John Wiley and Sons Inc
– name: Wiley
References e_1_3_1_43_2
e_1_3_1_22_2
e_1_3_1_45_2
e_1_3_1_24_2
e_1_3_1_8_2
e_1_3_1_41_2
e_1_3_1_20_2
e_1_3_1_4_2
e_1_3_1_6_2
e_1_3_1_26_2
e_1_3_1_47_2
e_1_3_1_2_2
e_1_3_1_28_2
e_1_3_1_49_2
e_1_3_1_32_2
e_1_3_1_34_2
e_1_3_1_13_2
e_1_3_1_51_2
e_1_3_1_11_2
e_1_3_1_30_2
e_1_3_1_17_2
e_1_3_1_15_2
e_1_3_1_36_2
e_1_3_1_19_2
e_1_3_1_38_2
e_1_3_1_21_2
e_1_3_1_44_2
e_1_3_1_23_2
e_1_3_1_46_2
e_1_3_1_7_2
e_1_3_1_40_2
e_1_3_1_9_2
e_1_3_1_42_2
e_1_3_1_29_2
e_1_3_1_3_2
e_1_3_1_5_2
e_1_3_1_25_2
e_1_3_1_48_2
e_1_3_1_27_2
e_1_3_1_33_2
e_1_3_1_35_2
e_1_3_1_12_2
e_1_3_1_50_2
e_1_3_1_10_2
e_1_3_1_31_2
e_1_3_1_52_2
e_1_3_1_16_2
e_1_3_1_14_2
e_1_3_1_37_2
e_1_3_1_18_2
e_1_3_1_39_2
References_xml – ident: e_1_3_1_39_2
  doi: 10.1161/01.CIR.0000017861.00991.2F
– ident: e_1_3_1_29_2
  doi: 10.1161/CIRCULATIONAHA.113.004046
– ident: e_1_3_1_38_2
  doi: 10.1016/j.amjcard.2010.09.026
– ident: e_1_3_1_20_2
  doi: 10.1016/j.jacc.2019.03.529
– ident: e_1_3_1_30_2
  doi: 10.1093/aje/kwy139
– ident: e_1_3_1_23_2
  doi: 10.1016/S0140-6736(15)00805-3
– ident: e_1_3_1_42_2
  doi: 10.1161/CIRCHEARTFAILURE.115.002460
– ident: e_1_3_1_16_2
  doi: 10.1161/CIRCOUTCOMES.118.005624
– ident: e_1_3_1_45_2
  doi: 10.1001/jamacardio.2019.6192
– ident: e_1_3_1_49_2
  doi: 10.1001/jama.2016.7050
– ident: e_1_3_1_19_2
  doi: 10.1093/ije/dyy264
– ident: e_1_3_1_36_2
  doi: 10.1016/S0149-2918(01)80109-0
– ident: e_1_3_1_5_2
  doi: 10.1161/CIRCULATIONAHA.116.025322
– ident: e_1_3_1_7_2
– ident: e_1_3_1_31_2
  doi: 10.1001/jamacardio.2021.3508
– ident: e_1_3_1_33_2
  doi: 10.3310/hta7310
– ident: e_1_3_1_51_2
  doi: 10.1161/JAHA.120.016174
– ident: e_1_3_1_24_2
  doi: 10.1161/CIR.0000000000000758
– ident: e_1_3_1_32_2
  doi: 10.1016/S0140-6736(15)01225-8
– ident: e_1_3_1_12_2
  doi: 10.7326/M17-1805
– ident: e_1_3_1_25_2
  doi: 10.1177/0272989X06290495
– ident: e_1_3_1_46_2
  doi: 10.1001/jamainternmed.2020.0051
– ident: e_1_3_1_21_2
  doi: 10.1001/jama.289.19.2560
– ident: e_1_3_1_37_2
  doi: 10.1136/bmj.39553.670231.25
– ident: e_1_3_1_6_2
  doi: 10.1093/ajh/hpad047
– ident: e_1_3_1_35_2
  doi: 10.1161/HYPERTENSIONAHA.109.148791
– ident: e_1_3_1_11_2
  doi: 10.1161/HYPERTENSIONAHA.122.20292
– ident: e_1_3_1_13_2
  doi: 10.1016/j.amepre.2014.03.004
– ident: e_1_3_1_18_2
  doi: 10.1161/CIRCULATIONAHA.120.051683
– ident: e_1_3_1_9_2
  doi: 10.3399/BJGP.2022.0389
– ident: e_1_3_1_22_2
  doi: 10.1001/jamanetworkopen.2021.43001
– ident: e_1_3_1_26_2
  doi: 10.1016/S0140-6736(12)61689-4
– ident: e_1_3_1_52_2
  doi: 10.1093/ajh/hpy053
– ident: e_1_3_1_34_2
  doi: 10.1136/bmj.326.7404.1427
– ident: e_1_3_1_43_2
  doi: 10.1161/CIRCULATIONAHA.113.007787
– ident: e_1_3_1_50_2
  doi: 10.1371/journal.pmed.1004223
– ident: e_1_3_1_3_2
  doi: 10.1056/NEJMsa1616035
– ident: e_1_3_1_40_2
  doi: 10.1016/j.cardfail.2019.07.134
– ident: e_1_3_1_41_2
  doi: 10.1161/01.CIR.0000109691.16944.DA
– ident: e_1_3_1_48_2
  doi: 10.1111/jgs.16749
– ident: e_1_3_1_44_2
  doi: 10.1161/JAHA.120.020361
– ident: e_1_3_1_15_2
  doi: 10.1056/NEJMoa1717250
– ident: e_1_3_1_28_2
  doi: 10.1161/CIRCULATIONAHA.113.004042
– ident: e_1_3_1_14_2
  doi: 10.1161/CIRCULATIONAHA.118.038165
– ident: e_1_3_1_17_2
  doi: 10.1038/s41371-023-00811-3
– ident: e_1_3_1_10_2
  doi: 10.1161/HYP.0000000000000065
– ident: e_1_3_1_27_2
  doi: 10.1016/j.jchf.2016.02.007
– ident: e_1_3_1_47_2
  doi: 10.1161/JAHA.120.019707
– ident: e_1_3_1_4_2
  doi: 10.1001/jamacardio.2016.3517
– ident: e_1_3_1_8_2
  doi: 10.1016/j.jacc.2021.02.058
– ident: e_1_3_1_2_2
  doi: 10.1056/NEJMoa1511939
SSID ssj0000627359
Score 2.3879364
Snippet Despite reducing cardiovascular disease (CVD) events and death in SPRINT (Systolic Blood Pressure Intervention Trial), intensive systolic blood pressure goals...
BACKGROUNDDespite reducing cardiovascular disease (CVD) events and death in SPRINT (Systolic Blood Pressure Intervention Trial), intensive systolic blood...
Background Despite reducing cardiovascular disease (CVD) events and death in SPRINT (Systolic Blood Pressure Intervention Trial), intensive systolic blood...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage e032370
SubjectTerms Adult
Antihypertensive Agents - pharmacology
Antihypertensive Agents - therapeutic use
Blood Pressure
cardiovascular diseases
Cardiovascular Diseases - epidemiology
Humans
hypertension
Hypertension - diagnosis
Hypertension - drug therapy
Hypertension - epidemiology
Original Research
Risk Factors
United States - epidemiology
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3BTtwwELUQh6oXBG2BhRa5EgcuAcd2bKe3bQVaIcEFVuJmxY4NK0EWscuBG5_AJ_At_ZR-SWfiLOyiSlx6TWLFmpfMvLHHbwjZjVzXNfchCwBvJisuMojzMVNFzaVhkWmHh5NPTtVgKI8viou5Vl9YE5bkgZPhDjTwa-kNK2olJI_CQUTC7bjgygDcPnlfxueSqeSDISwXZaflA6zm4Lg_wIU_sc8EF9iaeC4MtWr9_6KYbysl50LP0SpZ6Tgj7ae5rpGl0HwiH066XfHP5DJJEHd-i44jHUB2edfWpo8b-lrhQmdatGFCRw1tSyHO_zw-HWJZsrsOdHhG-yjIMflB-7-fz0Y3XXMviuWGD1_I8Ojw_Ncg6xooZF4qNs1KkYfSS8Mj6gRGUXihZKxzHZWXDlKtykTjGZg0Oi0rF1Tu8soEp0qpUYltnSw34yZsEupL7itgd0rFXOoYDCthFKvrGhABz9AjezN72tukk2Hb_ELlFk1vwfQ2mb5HfqK9Xx5Dgev2AsBuO9jte7D3yPcZWhZ-CNzlqJowvp9Yjor3GtO8HtlI6L28ShhUmNMw2izgujCXxTvN6KoV3c5ZyZVhfOt_zH6bfORAjnApJ1dfyfL07j58A3IzdTvtd_wX9a_2TA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3bbtQwELVQkaq-IO6Em4zEAy8pvsV2kBBaUKtVpeWlXalvVuzYsFJJYHcr0b_hW_gyZhJvy6LlNYnjyMfjmWNPzhDyOgnTtiLEMgK8pWqELMHPp1JXrVCWJWY8_pw8-6ync3VyXp3flAPKA7jaSe2wntR8eXH488fVBzD494PBa_72ZDLFPT15yKSQBvj7bQFuEfO7ZjnWH5dl8NRVneV9drQ7IPvSogKZEVtOatDy3xWA_ptH-ZdjOr5L7uSIkk7GKXCP3IrdfbI_y2fmD0gcBYrzqkb7RKfAPZdD5nrf0Zv8F7pRqo0ruujokChxVh5hyrK_iHR-Sico1rF6Rye_f50uvuXCXxRTEa8ekvnx0dmnaZmLK5RBabYua8ljHZQVCTUEk6yC1Cq13CQdlAca1thkA_OWJ29U46Pmnjc2el0rgyptj8he13fxCaGhFqGByE_rxJVJ0bIaWrG2baWHeFQW5M1mNN33UUPDDdxDc4cYOMDAjRgU5COO9vVjKH49XOiXX1y2JWeAcqlgWdVqqUSCTrjAE9ro6wh0TxTk1QYrB8aCJyBNF_vLlROohm-QAhbk8YjddVcb7Atit1Dd-pbtO93i6yDIzVkttGXi6X9f-owcCIiGcO-G6-dkb728jC8gmln7l8Ms_QN6H_AY
  priority: 102
  providerName: Scholars Portal
Title Effectiveness of Hypertension Management Strategies in SPRINT-Eligible US Adults: A Simulation Study
URI https://www.ncbi.nlm.nih.gov/pubmed/38214272
https://search.proquest.com/docview/2915571148
https://pubmed.ncbi.nlm.nih.gov/PMC10926802
https://doaj.org/article/76664c805d6342f3b8120464eb9e9562
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV27btswFCWSDEWXou-qj4AFOnSRzZdIqpsbJDACuCiQGMhGiBSZGoilwHaGbPmEfkK_pZ-SL8klJaVx0amLBkkEBR6K91zy8BChT4GpumbO5x7gzUXFeA5xPuSyqJnQJBBl4-bk2Tc5nYvjs-JsB8lhL0wS7Tu7GDUXy1Gz-JG0lZdLNx50YuPvswNKSiY1YeNdtAvx90GO3o2_EJKLsvfxAUYzPp5M46QfHxHOuIqHv3EdrcYU24pGybT_X0zzb8Hkgwh09BQ96akjnnSf-Azt-OY5ejTrF8dfoPPOibgfvnAb8BSSzFWSqLcN_iN0wYMlrV_jRYOTIuL09ubnYVQn2wuP5yd4En051l_w5Pevk8WyP-MLR9Xh9Us0Pzo8PZjm_TkKuROSbPKSU186oVmIdoGBF45LEWqqgnTCQsZV6aAdsZoGq0RlvaSWVtpbWQoVDdleob2mbfwbhF3JXAUkT8pAhQpekxJKkbquuQXqyTP0eWhPc9nZZZiUZkhqIgoGUDAdChn6Gtv7_rXoc51utKtz06NtFGRXwmlS1JILFqASyuJirLelh8yOZejjgJaB_yIudlSNb6_WhkXjexWzvQy97tC7r2pAP0N6C9etb9l-Al0xeW8PXe_t_xd9hx4zYEZxHofK92hvs7ryH4DZbOx-mhGA60zo_dSp7wBTAfqe
link.rule.ids 230,314,727,780,784,864,885,2102,24318,27924,27925,53791,53793
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFL0qRQI2iDfhaSQWbDLjV2yH3VC1CqVTIXVG6s6KHbuM1EmqmemCHZ_AJ_AtfApfgp1H6SBWbJNYtnwc33Pt42OAt57KqqLWpS7Am_KSsjTEeZ-KrKJcYY-liYeTp8eimPPD0-x0B8RwFqYV7VuzGNXny1G9-NJqKy-WdjzoxMafp3sE51QoTMc34GbGZE6uZendDByCcpb3Tj6B04wPJ0Vc9mMjzCiT8fo3pqLZmKRb8ai17f8X1_xbMnktBh3cg7s9eUSTrpH3YcfVD-DWtN8efwhnnRdxP4GhxqMipJmrVqTe1OiP1AUNprRujRY1ajURs1_fvu9HfbI5d2h-gibRmWP9Hk1-_jhZLPtbvlDUHX59BPOD_dlekfY3KaSWC7xJc0ZcbrmiPhoGepZZJriviPTCchNyrlJ5ZbFRxBvJS-MEMaRUzoicy2jJ9hh266Z2TwHZnNoy0DwhPOHSO4XzUApXVcVMIJ8sgXdDf-qLzjBDt4mGIDqioAMKukMhgQ-xv68-i07X7YNmdaZ7vLUM-RW3CmeVYJz6UAmhcTvWmdyF3I4m8GZAS4c_I253lLVrLteaRut7GfO9BJ506F1VNaCfgNrCdast22_CYGzdt4fB9-z_i76G28VseqSPPh5_eg53aOBJcVWHiBewu1ldupeB52zMq3ZQ_wbboPwk
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFLWgSBUbRHmGtmAkFmwy8Su2w24oHQ2FqSq1I3Vnxa8yUicZzUwX3fEJfALfwqf0S7DzKB3Eim0Sy1bOje-59skxAO88EdYS41IX4E1ZSWga8rxPeW4Jk8gjoePPyZNjPp6yo_P8vFNVrjpZZWX0bFBdzgfV7FujrVzMTdbrxLKTyQFGBeESkWxhfXYfPMhpiLI7lXo7C4fEnBedm0_gNdnRcByX_ugAUUJFPAKOymg4JshGTmqs-__FN_-WTd7JQ6PH4FFHIOGwHegOuOeqJ2B70m2RPwUXrR9xN4nB2sNxKDWXjVC9ruAfuQvsjWndCs4q2Ogizm6-_ziMGmV96eD0FA6jO8fqAxz--nk6m3cnfcGoPbx-Bqajw7ODcdqdppAaxtE6LSh2hWGS-Gga6GluKGfeYuG5YTrUXaX00iAtsdeCldpxrHEpneYFE9GW7TnYqurKvQTQFMSUgepx7jET3klUhFbIWkt1IKA0Ae_796kWrWmGaooNjlVEQQUUVItCAj7G9337WHS7bi7UywvVYa5EqLGYkSi3nDLiQyeYxC1ZpwsX6juSgLc9Wip8HXHLo6xcfbVSJNrfi1jzJeBFi95tVz36CZAbuG6MZfNOCMjGgbsPwFf_3_QN2D75NFJfPx9_2QUPSaBKcWEH8z2wtV5euf1Addb6dRPTvwF8b_03
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effectiveness+of+Hypertension+Management+Strategies+in+SPRINT-Eligible+US+Adults%3A+A%C2%A0Simulation+Study&rft.jtitle=Journal+of+the+American+Heart+Association&rft.au=Zhang%2C+Fengdi&rft.au=Bryant%2C+Kelsey+B&rft.au=Moran%2C+Andrew+E&rft.au=Zhang%2C+Yiyi&rft.date=2024-01-16&rft.eissn=2047-9980&rft.volume=13&rft.issue=2&rft.spage=e032370&rft_id=info:doi/10.1161%2FJAHA.123.032370&rft_id=info%3Apmid%2F38214272&rft.externalDocID=38214272
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2047-9980&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2047-9980&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2047-9980&client=summon